Small-molecule PHD inhibitors are approved/in clinical trials for the treatment of anaemia associated with chronic kidney diseases18,19, which is presently treated with erythropoietin (EPO), a common medicine for anaemia20. The gene discussed is EPO; the disease is anemia (phenotype).